News

Faron has also recently received the second IDMC (Independent Data Monitoring Committee) recommendation to continue the INTEREST pan-European Phase III trial with Traumakine without any modifications. ARDS is

The first drug candidate within the expanded scope, (CAM2058), is an extended release injectable combination of buprenorphine and granisetron in the FluidCrystal® injection depot technology. CAM2058 has completed

One study showed that people with VTE taking XARELTO® for longer than three months had a lower risk of VTE recurrence, without an increase in major bleeding, compared

The company seeks to expand the use of Opdivo to patients with locally advanced unresectable or metastatic urothelial carcinoma (mUC) that has progressed on or after platinum-containing therapy. The

In the '482 study, a total of 1,718 patients were randomized to receive either subcutaneous XGEVA 120 mg and intravenous placebo every four weeks, or intravenous zoledronic acid

The recently initiated Phase II study is the first clinical investigation of SNF472 in patients with newly diagnosed calciphylaxis. Designed as an open-label investigation, eligible patients will be

The drug, revefenacin, a once-daily nebulized bronchodilator, met primary efficacy endpoint and is shown to be well-tolerated in both studies. The studies, which lasted for 12 weeks, included

Under the agreement, NBE and Sotio will collaborate on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets. The ADC products will be based on

The compound, named RXC005, has the potential to treat the majority of patients suffering from Chronic Lymphocytic Leukaemia (CLL), including those who become resistant to the increasingly used